Authors' recommendations: Asthma is a long-term condition that affects the lungs and breathing. People with asthma may have coughing, wheezing, chest tightness and breathlessness. Most people can control their symptoms with treatment for most of the time, but some people still have symptoms despite treatment or may suffer from more sudden 'asthma attacks'. Severe asthma attacks can lead to hospitalisation, and on rare occasions can be life threatening. Lebrikizumab is a new drug to help people with severe asthma and needs to be injected under the skin. Some studies have suggested that lebrikizumab can help control severe asthma when other drugs have failed to do so. More studies are trying to show how well lebrikizumab works and whether it is safe to use. If lebrikizumab is licenced for use in the UK, it could be a new treatment option for patients with severe asthma.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/lebrikizumab-for-severe-asthma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)